Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtech's Unfinished Business For Congress In 2018: What's Ahead

Executive Summary

US Congress successfully pushed through a user-fee bill in 2017 to help smooth the regulatory path at FDA for medical devices and other products, but other efforts, including several industry priorities, remain undone. On top on the list, of course, is the effort to repeal the device excise tax. But legislation is also on the table to address diagnostics regulation, telehealth reimbursement, and medtech cybersecurity vulnerability, among other issues. Here is a look at the medtech landscape in Congress in 2018.

Advertisement

Related Content

Hello Device Tax, We Hardly Missed You: Companies Seek IRS Action To Stall Tax
Medtech-Supporter Sen. Al Franken To Resign, After Harassment Charges
US FDA Chief Favors LDT Approach In Bucshon-DeGette Bill
Medtech To Benefit From 20% Corporate Rate, Tax-Free Foreign Transfers In Pending US Tax Bill
AdvaMed CEO: Less Optimistic On Full Device Tax Repeal By Deadline
Gottlieb At The Medtech Conference: US FDA Commissioner Talks About CDRH Innovation, Puerto Rico, LDTs And More
'It's Time': AdvaMed Device Tax Ad Campaign Sets Sights On Key Lawmakers
House To Link Inspections, 3rd-Party Servicer, OTC Hearing Aid Bills To User-Fee Train
Lab Professionals Oppose Draft Dx Reform Bill; Lab, IVD Industry Ready To Work With Congress
Two-Year Ban On Device Tax Approved In Tax-Extenders Bill

Topics

Advertisement
UsernamePublicRestriction

Register

MT121983

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel